For the Inventor, By the Inventor

Enter assignee name

Langley, Canada

Anormed, Inc.

USPTO Granted Patents = 40

% Expired Patents = 22.5

CIPO Patents = 5

EPO Patents = 2

Forward Citations = 749

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Gary James Bridger (23 out of 45 patents)

Renato Skerlj (19 out of 33 patents)

Dominique Schols (16 out of 31 patents)

4. David Earl Bogucki (15 out of 32 patents)

5. Ernest John McEachern (13 out of 43 patents)

6. Trevor R Wilson (11 out of 16 patents)

7. Jason B Crawford (11 out of 18 patents)

8. Curtis Harwig (10 out of 32 patents)

9. Yuanxi Zhou (10 out of 40 patents)

10. Al Kaller (10 out of 18 patents)

11. Siqiao Nan (10 out of 16 patents)

12. Bem Atsma (8 out of 12 patents)

13. Michael J Abrams (7 out of 32 patents)

14. Christopher Dennis Smith (5 out of 9 patents)

15. Eva Maria Boehringer (5 out of 7 patents)

Core Competencies:

Chemokine Receptors

Antiviral Compounds

Stem Cell Mobilization

Amino-Substituted Rings

CXCR4 Antagonist

Platinum Complexes

Immunosuppressive Compositions

Cytokine Inhibitors

Pharmaceutical Compositions

Bicyclic Rings

Antitumor Agents

Substituted Azaspiranes

40 patents: Sort by Forward Citations

1. 7452994 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2008-11-18),

2. 7354934 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),

3. 7354932 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),

4. 7332605 - Process for the synthesis of CXCR4 antagonist (2008-02-19),

5. 7312234 - Chemokine receptor binding heterocyclic compounds (2007-12-25),

6. 7183273 - Chemokine receptor binding heterocyclic compounds (2007-02-27),

7. 7169750 - Methods to mobilize progenitor/stem cells (2007-01-30),

8. 7160872 - Methods to treat conditions mediated by chemokine receptors (2007-01-09),

9. 7135570 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2006-11-14),

10. 7091217 - Chemokine receptor binding heterocyclic compounds (2006-08-15),

11. 7084155 - Chemokine receptor binding heterocyclic compounds (2006-08-01),

12. 7022717 - Chemokine receptor binding heterocyclic compounds (2006-04-04),

13. 6987102 - Methods to mobilize progenitor/stem cells (2006-01-17),

14. 6894049 - Platinum complexes as antitumor agents (2005-05-17),

15. 6872714 - Methods to modulate conditions mediated by the CXCR4 receptor (2005-03-29),

Company Overview

Anormed, Inc., based in Langley, Canada, specializes in the development of innovative therapeutic agents targeting various medical conditions. The company focuses on advanced research in areas such as chemokine receptor binding and progenitor cell mobilization, with a particular emphasis on CXCR4 antagonists. Their portfolio includes antitumor agents and antiviral compounds, leveraging unique technologies involving amino-substituted bicyclic rings and platinum complexes to enhance white blood cell function and improve treatment outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

40 Patents

#1 in Langley

#345 in Canada

#17,087 in the World

Langley, Canada

Anormed, Inc.

Forward Citations = 749

50 inventors:

Gary James Bridger (23 out of 45 patents)

Renato Skerlj (19 out of 33 patents)

Dominique Schols (16 out of 31 patents)

4. David Earl Bogucki (15 out of 32 patents)

5. Ernest John McEachern (13 out of 43 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anormed, Inc.. Retrieved from https://idiyas.com/company/anormed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…